1 |
Jones-Tabah J. Targeting G Protein-Coupled Receptors in the Treatment of Parkinson's Disease. J Mol Biol 2022;:167927. [PMID: 36563742 DOI: 10.1016/j.jmb.2022.167927] [Reference Citation Analysis]
|
2 |
Zhang L, Li C, Zhang Z, Zhang Z, Jin Q, Li L, Hölscher C. DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model. Parkinson's Disease 2022;2022:1-11. [DOI: 10.1155/2022/1428817] [Reference Citation Analysis]
|
3 |
Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 2022;239:108277. [DOI: 10.1016/j.pharmthera.2022.108277] [Reference Citation Analysis]
|
4 |
Varesi A, Campagnoli LIM, Fahmideh F, Pierella E, Romeo M, Ricevuti G, Nicoletta M, Chirumbolo S, Pascale A. The Interplay between Gut Microbiota and Parkinson's Disease: Implications on Diagnosis and Treatment. Int J Mol Sci 2022;23:12289. [PMID: 36293176 DOI: 10.3390/ijms232012289] [Reference Citation Analysis]
|
5 |
Shen Z, Yu M, Zhang S, Surguchov A. Network Pharmacology and Molecular Docking Analyses Unveil the Mechanisms of Yiguanjian Decoction against Parkinson’s Disease from Inner/Outer Brain Perspective. BioMed Research International 2022;2022:1-25. [DOI: 10.1155/2022/4758189] [Reference Citation Analysis]
|
6 |
Reich N, Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci 2022;16:970925. [DOI: 10.3389/fnins.2022.970925] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|